The city of Minneapolis, Minnesota, currently has 2 active clinical trials seeking participants for Multiple Sclerosis research studies.
Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Recruiting
This is a multi-center prospective rater-masked (blinded) randomized controlled trial of 156 participants, comparing the treatment strategy of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) to the treatment strategy of Best Available Therapy (BAT) for treatment-resistant relapsing multiple sclerosis (MS). Participants will be randomized at a 1 to 1 (1:1) ratio. All participants will be followed for 72 months after randomization (Day 0, Visit 0).
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
01/26/2024
Locations: University of Minnesota Multiple Sclerosis Center, Minneapolis, Minnesota
Conditions: Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
Recruiting
The DELIVER-MS study seeks to answer the question: Does early treatment with highly effective DMT improve the prognosis for people with MS? This is an area of significant controversy and no data currently exist to guide treatment choices for patients and clinicians. The study results will help guide overall treatment philosophy and will be applicable not only to a wide range of existing therapies but also to new therapies, meeting a significant unmet need in patient decision making and aiding th... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
08/14/2023
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Multiple Sclerosis, Relapsing-Remitting